Working Together To Make Rabies History!

Working Together To Make Rabies History!
Organisations around the world will be aiming to raise awareness and understanding about the importance of rabies prevention on the second annual World Rabies Day on September 28. Rabies is known as the 'oldest and deadliest disease known to mankind' and the BVA, through its Overseas Group, is supporting this initiative.

What Is The Risk Factor For Severe Clostridium Difficile-Associated Diarrhea?
Clostridium difficile associated diarrhoea (CDAD) is the most common cause of healthcare-associated diarrhoea and results in a wide spectrum of disease severity ranging from asymptomatic carriage to life-threatening entero-colitis and death. While many studies have investigated risk factors for infection with C. difficile and subsequent development of CDAD, little is known about risk factors associated with a severe course of CDAD in hospitalised patients.

The Side Effects Of Monotherapy With Lamivudine
Lamivudine has a high rate of antiviral resistance. Sequential anti-HBV treatment is commonly used for lamivudine resistance. We report 4 cases with rapid re-detection of HBV mutants during the lamivudine re-treatment. The article was published in the World Journal of Gastroenterology. In this report, four patients received lamivudine as an initial treatment of HBV. They had adefovir and lamivudine as a rescue therapy consecutively.

A New Therapeutic Option For Human Hepatocyte Cancer
Tumors that are p53-impaired may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities.

What Is The Best Strategy For Treating Helicobacter Pylori?
The most popular treatment for H pylori is triple therapy but resistance to Clarithromycin is reducing its effectiveness. Courses using four drugs have been known to be more successful but are used less popular because of their side-effects. While, what is the best way for treating H pylori-related diseases. A research article to be published on 28 June 2008, in the World Journal of Gastroenterology addresses this question. The research team led by Prof.